All members have the option of attending our various HTC-centric events which include:
Date: Thursday, June 26th, 2025 Time: 1:00pm - 2:00pm ET WEBINAR TITLE: Washington Update SESSION OBJECTIVE: Come to hear the latest on actions in Washington that could impact your HTC and your patients – from 340B reform and federal funding for hemophilia programs, to Congress’ “One Big Beautiful Bill” and how it could Read the full article...
Date: July 16th - 17th Location: Indianapolis, IN
Date: Tuesday, July 22nd, 2025 Time: 1:00pm - 2:00pm ET WEBINAR TOPIC: Review the clinical benefits of wilate®, highlighting the benefits vs current vWD therapies. OBJECTIVES: Understand the attributes of wilate® for vWD: 1:1 ratio which mimics the physiologic activity of vWF and FVIII and the synchronous decay curves, which facilitates Read the full article...
Date: Tuesday, August 12th, 2025 Time: 1:00pm - 2:00pm ET WEBINAR TITLE: Big Bill, Big Insurance Impact - What do HTCs need to know now about coming health insurance changes and how to prepare? SESSION OBJECTIVE: The One Big Beautiful Bill Act and other Washington policies are reshaping the insurance landscape for HTCs Read the full article...
Date: August 21st - 23rd Location: Denver, CO
Date: Wednesday, August 27th, 2025 Time: 2:00pm - 3:00pm ET WEBINAR TITLE: Juggling Fall Routines Can Be Complicated. Help your patients keep their hemophilia treatment simple with subcutaneous HYMPAVZI (marstacimab-hncq): Learn More From a Real-World Patient Experience. OBJECTIVES: To educate attendees on challenges, shared decision making in hemophilia and introduce Read the full article...
Date: Thursday, September 4th, 2025 Time: 1:00pm - 2:00pm ET WEBINAR TITLE: Advancing Care with ROCTAVIAN® (valoctocogene roxaparvovec-rvox): Clinical Evidence, Patient Perspective & Contract Opportunities. OBJECTIVES: Explore updates to HEM Alliance member contract terms and the associated provider economics. Review the latest clinical data updates, describing the long-term efficacy and safety of Read the full article...
Date: Wednesday, September 10th, 2025 Time: 1:00pm - 2:00pm ET WEBINAR TITLE: Mental Health and Substance Use in the Bleeding Disorders Community. DESCRIPTION: The bleeding disorders community does not have the same access to inpatient and residential mental health and substance use treatment that the general population does. This webinar will Read the full article...
Date: Wednesday, September 17th, 2025 Time: 2:00pm - 3:00pm ET WEBINAR TOPIC: Qfitlia Overview: Clinical, Access, and Distribution Dynamics. OBJECTIVE: Dr. Lynn Malec will review key elements of the Qfitlia efficacy and safety profile and Adam Gurry, Sanofi Director of Access Strategy, will provide insights on the Qfitlia access and distribution strategy. Read the full article...
Date: Wednesday, October 1st, 2025 Time: 1:00pm - 2:00pm ET WEBINAR TOPIC: On-demand and Surgical Use of ADVATE® OBJECTIVE: This session will explore critical aspects of hemophilia A management, focusing on the unique role of ADVATE in on-demand and perioperative settings. AUDIENCE: All HTC Staff. SPEAKER: Jessica Grandoni, Pharm.D., BCPS, was the Read the full article...
Date: October 5 - 7, 2025 Location: Washington, DC Agenda Overview Sunday, October 5th – Networking Reception 6:30pm - 8:30pm Monday, October 6th – Breakfast at 7:30am, followed by Meeting 8:30am - 6:30pm, to include our Hill Day Training and Dinner to follow Tuesday, October 7th – Breakfast then Hill Day (schedules TBD) Read the full article...
Date: Thursday, October 23rd, 2025 Time: 3:00pm - 4:00pm ET WEBINAR TITLE: Revolutionizing Hemophilia A Patient Care: Nurses’ Insights on the First Subcutaneous Prophylaxis Treatment for Hemophilia A. DESCRIPTION: Please join us for an engaging discussion featuring nurses Jennifer Maahs, RN, PNP, MSN and Joseph Stanco, MSN, DNP, CCRC as they share Read the full article...
Date: Thursday, October 30th, 2025 Time: 2:00pm - 3:00pm ET WEBINAR TOPIC: Alhemo (concizumab-mtci): A new option for patients living with hemophilia. OBJECTIVE: To provide an update on prescribing information of the recently FDA-approved indication in patients with hemophilia A or B without inhibitors, and supporting data from the explorer8 trial. AUDIENCE: Read the full article...
Date: January 11 - 13, 2026 Location: Newport Beach, CA Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
Date: January 21 - 23, 2026 Location: TBD Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
Date: February 25 - 27, 2026 Location: Oklahoma City, OK Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
Date: March 8 - 10, 2026 Location: TBD Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
Date: April 21 - 23, 2026 Location: TBD Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
Date: May 3 - 5, 2026 Location: TBD Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
Date: May 6 - 8, 2026 Location: TBD Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
